Introduction
Developmental heart malformations are the most frequently identified congenital anomaly in children [2] . Among these, heart valve defects often require the defective valve to be replaced in a surgical procedure. Thereafter, the integrity and function of the valve must be followed carefully. However, little is known about the genes that regulate the integrity and maintenance of valve function throughout the post-natal period and adulthood.
The nuclear factor of activated T cells (NFAT) family of transcription factors was first identified in immune cells [3] . There are four isoforms of this protein, NFATc1, c2, c3, and c4 (alternative names are NFAT1-4). While knockout of other NFAT proteins produces defects in the immune system or other organs [4, 5] , knockout of NFATc1 blocks the formation of the pulmonary and aortic valves, causing embryonic lethality at embryonic day (ED) 14-15 [6, 7] . Cyclosporin A (CsA) is an inhibitor of calcineurin, a phosphatase that activates NFATs and allows their translocation into the nucleus where they then regulate transcription. Thus, CsA inhibits calcineurin-NFAT signaling pathways [5] . Vascular endothelial growth factor-A (VEGF-A), a central regulator of angiogenesis and vasculogenesis, activates NFATc1 in human valve endothelial cells isolated from normally discarded surgical specimens [1] . We and others showed previously that VEGF-A rapidly activates NFATc1 translocation into the nucleus and that this is required for the full mitogenic activity of VEGF-A in human pulmonary valve endothelial cells (HPVECs) [1, 8] .
The primordial heart valve cushions are defined by swellings in the atrioventricular (AV) junction and outflow tract at ED 9.5 in mice. The cushion is initially made up of extracellular matrix components, but as endocardial endothelial cells are stimulated to undergo endothelial-mesenchymal transdifferentiation (EMT), the cellularity of the cushion increases due to the migration of endothelial cells [9] . The signals from myocardium that induce EMT of the endothelium are not well defined, but one strongly implicated factor is bone morphogenic protein-2 (BMP-2) [10] [11] [12] [13] . In clonal endothelial cells isolated from sheep heart valves, transforming growth factor (TGF)-b induces EMT significantly [14] .
In zebrafish, the jekyll mutant has a disruption in the gene encoding uridine 5 0 -diphosphate glucose dehydrogenase, which is essential for the synthesis of hyaluronic acid, an abundant component of the extracellular matrix in endocardial cushions [15] . The jekyll mutant zebrafish embryo exhibits regurgitation or toggling of blood between the atrium and ventricle as well as defects in cell differentiation at the AV boundary, indicating a defect in valve formation. Using a chemical approach, we tested the effect of adding a VEGF receptor-selective inhibitor to wild-type zebrafish embryos. Blocking VEGF-A signaling for 4 h induced a phenotype remarkably similar to that of the jekyll mutant [16] . This finding suggested that VEGF-A is a significant up-stream regulator of NFATc1 and implicated VEGF-A and VEGFR-2 in valvulogenesis. However, the down-stream targets of VEGF-NFATc1 signaling have not yet been identified in valve endothelial cells.
In this study, we investigated the genes that are up-and downregulated by VEGF-NFATc1 to further understand the function of VEGF-NFATc1 signaling in valve endothelial cells. Among up-regulated genes, Down Syndrome critical region 1 (DSCR1) and heparin-binding EGF-like growth factor (HB-EGF) showed opposing influences on the migration of HPVECs. Since increased migration is a key cellular event in EMT, these results suggest that NFATc1 activation by VEGF-A might affect specific cellular functions that are regulated during valvulogenesis.
Materials and methods

Cell culture
HPVEC and sheep aortic ovine valve endothelial cell (OVEC) were isolated from human pulmonary valve leaflets as described [1, 14] . The passages of HPVECs and OVECs used in this study were 6-9 and 9-13, respectively.
Immunofluorescence assay
HPVECs were fixed in 4% paraformaldehyde, permeabilized with 0.5% Triton X-100, and incubated with mouse anti-human NFATc1 monoclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) followed by FITC-conjugated anti-mouse IgG.
Western blot analysis
Equal amounts of protein extracts in a SDS-lysis buffer were subjected to 10% SDS-PAGE analysis and transferred to a nitrocellulose membrane. The anti-NFATc1 antibody used was obtained from Santa Cruz Biotechnology. An enhanced chemiluminescence system (Pierce, Woburn, MA) was used for detection.
Total RNA isolation and DNA microarray analysis
HPVEC cells were treated with VEGF (50 ng/ml) and with or without CsA (1 lg/ml) for 3 h. Total RNA was isolated from the treated cells by single-step procedure with Trizol reagent (Invitrogen, Gaithersburg, MD). The quality of total RNA (260/280 nm ratio) was excellent (above 2.0) and used for further cRNA synthesis and chip hybridization procedure with Gene Chip (HU133A, Affymetrix Inc., Santa Clara, CA). All microarray data were analyzed at the NetAffx Analysis Center on Affymetrix web site (http://www.affymetrix.com/analysis/index.affx).
Knock-down of DSCR1 and HB-EGF with siRNA
OVEC cells were transfected with double stranded RNA using a MicroPorator (NanoEnTek, Seoul, Korea). After transfection, cells were harvested for the detection of gene expression by semiquantitative RT-PCR. The scrambled control siRNA sequence was 5 0 -CUGAUGACCUGAGUGAAUGdTdT-3 0 , the DSCR1 sequence was 5 0 -CUGAUUGCCUGUGUGGCAA dTdT-3 0 , and the HB-EGF sequence was 5 0 -UGCCGUCGGUGGUGCUGAUGAAdTdT-3 0 (Bioneer, Daejeon, Korea).
Cell migration assay
The bottom of transwell filters (8 lm porosity polycarbonate filters, Costar, USA) was coated with 0.5 mg/ml type I collagen. The lower chamber of each well contained a low serum media with or without VEGF. In the upper chamber of the transwell plate, 5 Â 10 4 cells were resuspended in 1 ll EMB and plated. After 24 h, cells were fixed with methanol and stained with hematoxylin and eosin (Sigma, St. Louis, MO). The cells on the upper surface of the filter were removed and the cells that had migrated to the lower chamber were counted using a light microscope with a 200Â magnification objective. Each sample was assayed in triplicate, and repeated twice.
Statistical analysis
ANOVA tests were performed to assess the significance of differences between control and experimental groups. The level of significance was set at P < 0.01 or P < 0.05. Results are presented as the means ± S.D. (standard deviation). 
Results and discussion
VEGF stimulates the nuclear translocation of NFATc1 and CsA blocks NFATc1 activation
We previously studied the function of NFATc1 in valvular endothelium using HPVECs isolated from human pulmonary valve leaflets [1] . VEGF treatment (50 ng/ml) rapidly induced NFATc1 translocation into the nucleus within 30 min (Fig. 1A-b) ; this translocation was sustained for 3-5 h (Fig. 1A-c and data not shown) . CsA completely blocked the VEGF-induced NFATc1 translocation (Fig. 1A-d) . Long-term exposure to VEGF for 3 h sustained NFATc1 activation (Fig. 1A-c) . To confirm the activation of NFATc1 we performed a Western blot analysis and found that dephosphorylation of NFATc1 was induced by VEGF after 5 h and that treatment with CsA blocked the dephosphorylation of NFATc1, which could be seen as the lower mobility of the phosphorylated form on an SDS-PAGE gel (Fig. 1B) . However, the sustained treatment of VEGF (10 or 20 h) decreased NFATc1 protein level but showed the NFATc1 activation might occur independently of its protein level at these time points (Fig. 1B) . Thus, we collected total RNA from HPVECs after VEGF treatment for 3 h, with or without CsA, to identify the genes regulated by NFATc1 activation.
Genes regulated by VEGF stimulation
To identify genes regulated by VEGF-calcineurin pathway including NFATc1, and not by other VEGF-stimulated pathways, we compared gene expression levels (microarray results) from cells treated with VEGF to those from cells treated with VEGF plus CsA. VEGF-NFATc1 regulated genes would be increased or decreased by VEGF but not affected by VEGF plus CsA. Although CsA is an inhibitor of all calcineurin phosphatase activity, CsA treatment concurrent with VEGF treatment should block only NFATc1, because VEGF does not activate NFATc2, c3, or c4 in HPVECs [1] . However, we cannot exclude the possibility that some of our results are due to non-specific blocking of calcineurin pathways that do not involve NFATc1 [4] . We categorized the significantly up-regulated genes by biological functions: cell growthand differentiation-related, heart development-related, muscle development-related, Wnt signaling-related genes and viral infection-related genes ( Table 1) . A number of genes with roles in cardiac development were identified. For example, cystein-rich angiogenic inducer 61 (CYR61) regulates cell adhesion, migration, and proliferation through binding to integrin receptors and heparan sulfate proteoglycans. CYR61 deficient mice show severe atrioventricular septal defects (AVSD) accompanying endocardial cushion defects [17] . Another identified gene, HB-EGF, is known to function in cardiac valve morphogenesis, especially in regulating valve remodeling [18] . HB-EGF null mutant mice demonstrate enlarged semilunar and atrioventricular heart valves, indicating the role of this gene in the inhibition of mesenchymal cell proliferation [18, 19] . Dikkopf 1 (DKK1) is a secreted inhibitor of Wnt signaling that, when overexpressed, has an inhibitory effect on cardiac cushion formation in zebrafish [20] . Mutations in jagged-1, as in human Alagille syndrome, cause pulmonary valve stenosis [21] . Among [22] [23] [24] . However, many of the other up-regulated genes listed in Table 1 do not fully defined roles in cardiac development. Insulin-like growth factor binding protein (IGFBP)-2 was recently identified as an angiogenic or cardiogenic molecule in zebrafish [25] . IGFBPs bind to IGFs and might differentially regulate biological functions in a tissue-specific manner. IGFBP-3 expression is increased by serum deprivation and has an anti-proliferative effect in porcine endothelial cells [26] .
The genes that we identified as significantly down-regulated by VEGF-NFATc1 activation in HPVECs were highly relevant to vascular permeability and cardiac cell differentiation. Angiomotin, a receptor for the angiogenesis inhibitor, angiostatin, decreases VEGF-induced cell migration in vascular endothelial cells, especially at the polarization of endothelial branching [27] . Therefore, we can speculate that the VEGF-stimulated endocardial cell migration might be caused by the inhibition of angiomotin. BMP10 is highly expressed in Notch1 mutant embryos and was shown to increase myocardial proliferation during cardiac chamber formation [28] . However, further investigation of the role of BMP10 in endocardial cells of the cardiac valve is needed.
VEGF-A increases migration of HPVECs in a calcineurin-and kinase insert domain receptor (KDR)-dependent manner
To identify whether the VEGF-NFATc1 signaling pathway functions in specific cellular events that occur during EMT, we chose to perform a migration assay because increased migratory ability is feature of EMT [9, 29] . VEGF-treated HPVECs showed increased migration (1.4-fold, P < 0.01), but co-treatment with 0.5 lM CsA decreased cell migration to the control level ( Fig. 2A, P < 0.01) . This result suggests that calcineurin-dependent NFATc1 activation contributes to EMT by increasing the migration of valve endothelial cells. When cells were treated with KDR receptor-selective variant VEGF [30] , cell migration was almost equivalent to that of those treated with VEGF, suggesting that the effect of VEGF on HPVEC migration is mediated by VEGFR-2. In contrast, bFGF had no effect HPVEC migration (Fig. 2B) .
DSCR1 and HB-EGF induced by VEGF demonstrate opposing effects on the migration of valve endothelial cells
To further analyze the effect of VEGF on valve EMT, we selected two different genes among those up-regulated by VEGF compared to VEGF plus CsA. DSCR1 is a direct transcriptional target of Significant differences from untreated control cells were noted as *P < 0.01. (B) Cells were treated with bFGF (10 ng/ml), KDR-selective variant VEGF (50 ng/ml), or VEGF (50 ng/ml) and a migration assay was performed as described in (A). Significant differences from untreated control cells were noted as *P < 0.01. Data represent means ± S.D. of two different experiments. Each assay was performed in triplicate. NFATc1 and a negative feedback inhibitor of calcineurin [31] . HB-EGF knockout mice have thickened valves while NFATc1 knockout mice exhibit an absence of semilunar or atrioventricular valves [18, 19, 5] . However, HB-EGF was up-regulated by VEGF in our DNA microarray data. Thus we selected these two genes, DSCR1 and HB-EGF for further analysis.
To confirm the DNA microarray data for DSCR1 and HB-EGF, we performed semi-quantitative RT-PCR after cells were treated with VEGF in the presence or absence of CsA for 1, 3, or 6 h. The expression of DSCR1 and HB-EGF was significantly up-regulated by VEGF treatment alone versus co-treatment with VEGF and CsA until 6 h (Fig. 3A) . This confirms the results obtained from the DNA microarray, indicating that DSCR1 and HB-EGF are regulated by VEGFNFATc1 activation. Next, we performed migration assays with ovine cells in which either gene had been after knocked-down individually. The siRNA silencing of DSCR1 and HB-EGF worked well, as confirmed by semi-quantitative RT-PCR (Fig. 3B-a) . Interestingly, knock-down of DSCR1 significantly increased migration of OVECs (Fig. 3B-b and -d) compared to scrambled siRNA control, indicating that DSCR1 might function to inhibit valve EMT. However, knockdown of HB-EGF significantly decreased migration of OVECs (Fig. 3B-b and -e). This suggests that HB-EGF plays a positive role in the migratory capability of valve endothelial cells. Even though we did not treat cells with CsA in both case, we can expect that the treatment with CsA would not solely potentiate the results in both silenced cells because the treatment of CsA would inhibit a number of genes that might play different roles in the migration as these two genes did.
It has been suggested that DSCR1 functions as a negative feedback inhibitor for NFATc1 by inhibiting calcineurin [31] . It is thus important to define the precise cellular behaviors that are regulated by this feed-back inhibition. For example, VEGF-induced NFATc1 activation enhances the proliferation of HPVECs, suggesting that DSCR1 does not have a major effect on proliferation [7] . DSCR1 over-expression in OVECs does not inhibit EMT [32] . Here, our data suggest that DSCR1 inhibits valve EC migration. Therefore, it is possible that VEGF may inhibit or attenuate EMT through VEGF-induced DSCR1, which would in turn inhibit cellular migration [31, 33, 34] . Alternatively, VEGF might inhibit TGF-b-induced EMT through the activity of other genes. HB-EGF is suggested to stimulate valvulogenesis in some steps of cardiac development through the BMP signaling pathway [12, 13] . Interestingly, increased activation of BMP signaling molecules such as Smad1, 5, and 8 was observed in hyperplastic valves of HB-EGF mutants [18] , suggesting that HB-EGF may oppose BMP signaling. A positive function for VEGF in active cellular migration and EMT (our results, [35] ) might be mediated by HB-EGF. HB-EGF, therefore, appears to act as a negative regulator of mesenchymal cell proliferation but a positive regulator of valve endothelial cell migration during valve development and remodeling. Taken together, these results suggest that the VEGF-NFATc1 signaling pathway play a role in EMT homeostasis, which may involve the migration of valve endothelial cells.
